[{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Norepinephrine Bitartrate","moa":"||Adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Baxter Healthcare Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Baxter Healthcare Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BELGIUM","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2016","type":"Inapplicable","leadProduct":"Sodium Chloride","moa":"Adrenergic receptor Alpha-2 (ADRA2)","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"11","companyTruncated":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Cefazolin","moa":"Bacterial penicillin-binding protein","graph1":"Undisclosed","graph2":"Phase I","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Baxter Healthcare Corporation \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Baxter Healthcare Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Piperacillin Sodium","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Baxter Healthcare Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Baxter Healthcare Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"FRANCE","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Esmolol Hydrochloride","moa":"Beta-2 adrenergic receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"FRANCE","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Esmolol Hydrochloride","moa":"Beta-2 adrenergic receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Esmolol Hydrochloride","moa":"Beta-2 adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"11","companyTruncated":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Esmolol Hydrochloride","moa":"Beta-2 adrenergic receptor","graph1":"Undisclosed","graph2":"Phase III","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Dietary Supplement","year":"2010","type":"Inapplicable","leadProduct":"Glucose","moa":"Blood glucose level","graph1":"Nephrology","graph2":"Phase II","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Spectral Medical","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Agreement","leadProduct":"Polymyxin B Sulfate","moa":"Cell outer membrane","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Thrombin","moa":"Coagulation factor XI; Coagulation factor XIII A chain; Coagulation factor XIII B chain; Fibrinogen alpha chain; Fibrinogen beta chain; Fibrinogen gamma chain; Coagulation factor V; Coagulation factor VIII; Proteinase-activated receptor 1; Proteinase-activated receptor 4","graph1":"Oncology","graph2":"Phase III","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CANADA","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Thrombin","moa":"Coagulation factor XI; Coagulation factor XIII A chain; Coagulation factor XIII B chain; Fibrinogen alpha chain; Fibrinogen beta chain; Fibrinogen gamma chain; Coagulation factor V; Coagulation factor VIII; Proteinase-activated receptor 1; Proteinase-activated receptor 4","graph1":"Hematology","graph2":"Phase IV","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"11","companyTruncated":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Doxorubicin Hydrochloride","moa":"DNA topoisomerase II alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baxter Healthcare Corporation \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Baxter Healthcare Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Halozyme Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Enzyme","year":"2010","type":"Inapplicable","leadProduct":"Hylenex","moa":"enzymes","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Baxter Healthcare Corporation \/ Halozyme Therapeutics","highestDevelopmentStatusID":"11","companyTruncated":"Baxter Healthcare Corporation \/ Halozyme Therapeutics"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Antihemophilic Factor (Recombinant), Plasma","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Artiss Fibrin Sealant","moa":"Fibrin","graph1":"Undisclosed","graph2":"Phase II","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"INDIA","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Fibrin Sealant","moa":"Fibrinogen \/ Thrombin","graph1":"Dental and Oral Health","graph2":"Phase IV","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"11","companyTruncated":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Fibrin Sealant","moa":"Fibrinogen \/ Thrombin","graph1":"Neurology","graph2":"Undisclosed","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"1","companyTruncated":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Fibrin Sealant","moa":"Fibrinogen \/ Thrombin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Baxter Healthcare Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Baxter Healthcare Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Fibrin Sealant","moa":"Fibrinogen \/ Thrombin","graph1":"Hematology","graph2":"Phase II","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Baxter Healthcare Corporation \/ Bayer AG","highestDevelopmentStatusID":"8","companyTruncated":"Baxter Healthcare Corporation \/ Bayer AG"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Fibrin Sealant","moa":"Fibrinogen \/ Thrombin","graph1":"Neurology","graph2":"Phase III","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baxter Healthcare Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Baxter Healthcare Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Propofol","moa":"GABA-A receptor; anion channel","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"11","companyTruncated":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Olimel","moa":"Homeostasis","graph1":"Undisclosed","graph2":"Phase III","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Olimel","moa":"Homeostasis","graph1":"Nephrology","graph2":"Phase IV","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"11","companyTruncated":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"INDIA","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Prismocitrate 18","moa":"Homeostasis","graph1":"Nephrology","graph2":"Phase III","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"INDIA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Prismocitrate 18","moa":"Homeostasis","graph1":"Nephrology","graph2":"Phase III","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Enzyme","year":"2010","type":"Inapplicable","leadProduct":"Hyaluronidase","moa":"Hyaluronic acid","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"11","companyTruncated":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Halozyme Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Enzyme","year":"2010","type":"Inapplicable","leadProduct":"Recombinant Human Hyaluronidase","moa":"Hyaluronic acid; Transforming growth factor beta-1 proprotein","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Baxter Healthcare Corporation \/ Halozyme Therapeutics","highestDevelopmentStatusID":"11","companyTruncated":"Baxter Healthcare Corporation \/ Halozyme Therapeutics"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2019","type":"Inapplicable","leadProduct":"Olive","moa":"Immune","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"UT Southwestern Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Controlled Substance","year":"2011","type":"Inapplicable","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"11","companyTruncated":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"INDIA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Dianeal","moa":"Peritoneal dialysis","graph1":"Nephrology","graph2":"Phase III","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Pioglitazone","moa":"Peroxisome proliferator-activated receptor gamma","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"1","companyTruncated":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Carbohydrate","year":"2019","type":"Inapplicable","leadProduct":"Iron Sucrose","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Baxter Healthcare Corporation \/ Quotient Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Baxter Healthcare Corporation \/ Quotient Sciences"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Desflurane","moa":"Potassium channel subfamily K member 3 | Potassium channel subfamily K member 10 | GABA-A receptor; anion channel | Potassium channel subfamily K member 2 | Potassium channel subfamily K member 9 | Potassium channel subfamily K member 18 | Glycine receptor (alpha-1\/beta)","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"11","companyTruncated":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Desflurane","moa":"Potassium channel subfamily K member 3 | Potassium channel subfamily K member 10 | GABA-A receptor; anion channel | Potassium channel subfamily K member 2 | Potassium channel subfamily K member 9 | Potassium channel subfamily K member 18 | Glycine receptor (alpha-1\/beta)","graph1":"Oncology","graph2":"Undisclosed","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"1","companyTruncated":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Desflurane","moa":"Potassium channel subfamily K member 3 | Potassium channel subfamily K member 10 | GABA-A receptor; anion channel | Potassium channel subfamily K member 2 | Potassium channel subfamily K member 9 | Potassium channel subfamily K member 18 | Glycine receptor (alpha-1\/beta)","graph1":"Undisclosed","graph2":"Phase III","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Desflurane","moa":"Potassium channel subfamily K member 3 | Potassium channel subfamily K member 10 | GABA-A receptor; anion channel | Potassium channel subfamily K member 2 | Potassium channel subfamily K member 9 | Potassium channel subfamily K member 18 | Glycine receptor (alpha-1\/beta)","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase IV","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"11","companyTruncated":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Desflurane","moa":"Potassium channel subfamily K member 3 | Potassium channel subfamily K member 10 | GABA-A receptor; anion channel | Potassium channel subfamily K member 2 | Potassium channel subfamily K member 9 | Potassium channel subfamily K member 18 | Glycine receptor (alpha-1\/beta)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"11","companyTruncated":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Desflurane","moa":"Potassium channel subfamily K member 3 | Potassium channel subfamily K member 10 | GABA-A receptor; anion channel | Potassium channel subfamily K member 2 | Potassium channel subfamily K member 9 | Potassium channel subfamily K member 18 | Glycine receptor (alpha-1\/beta)","graph1":"Nephrology","graph2":"Phase IV","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"11","companyTruncated":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Sevoflurane","moa":"Potassium channel subfamily K member 3 | Potassium channel subfamily K member 10 | Potassium channel subfamily K member 18 | Glycine receptor (alpha-1\/beta) | Potassium channel subfamily K member 9 | Potassium channel subfamily K member 2 | GABA-A receptor; anion channel","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"11","companyTruncated":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Seoul National University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2010","type":"Inapplicable","leadProduct":"Continuous Renal Replacement Therapy","moa":"Renal replacement","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"1","companyTruncated":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Ropivacaine Hydrochloride","moa":"Sodium channel alpha subunit","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Catheter","sponsorNew":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"11","companyTruncated":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Ropivacaine Hydrochloride","moa":"Sodium channel alpha subunit","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Agreement","leadProduct":"TAK-919","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Baxter Healthcare Corporation \/ Moderna Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Baxter Healthcare Corporation \/ Moderna Therapeutics"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Alvotech","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2021","type":"Private Placement","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Baxter Healthcare Corporation","amount2":0.10000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0.10000000000000001,"dosageForm":"Injection","sponsorNew":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CHINA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Losartan Potassium","moa":"Type-1 angiotensin II receptor","graph1":"Nephrology","graph2":"Undisclosed","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"1","companyTruncated":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"FRANCE","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Arterial Blood Sampling","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"1","companyTruncated":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"BELGIUM","productType":"Dietary Supplement","year":"2018","type":"Inapplicable","leadProduct":"Back Side Of The Moon","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"1","companyTruncated":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Bovine Derived Gelatin Matrix","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"1","companyTruncated":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Bovine Derived Gelatin Matrix","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Baxter Healthcare Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Baxter Healthcare Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Clinolipid","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"Baxter Healthcare Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Baxter Healthcare Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Clinolipid","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"Baxter Healthcare Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Baxter Healthcare Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Electrolyte","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Baxter Healthcare Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Baxter Healthcare Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Enzyme","year":"2015","type":"Inapplicable","leadProduct":"Human Immunoglobulin with Recombinant Hyaluronidase","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Icodextrin","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"11","companyTruncated":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Icodextrin","moa":"Undisclosed","graph1":"Nephrology","graph2":"Undisclosed","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"1","companyTruncated":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Immune Globulin","moa":"Immunoglobulins||Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Immune Globulin","moa":"Immunoglobulins||Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Immune Globulin","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Plant Extract\/Herbal","year":"2014","type":"Inapplicable","leadProduct":"Intralipid","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"9","companyTruncated":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"United Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"MIRO-001 Bioengineered Liver Graft","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"IND Enabling","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"5","companyTruncated":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Numeta G13 E","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baxter Healthcare Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Baxter Healthcare Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Numeta G16","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Catheter","sponsorNew":"Baxter Healthcare Corporation \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Baxter Healthcare Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Olive","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Baxter Healthcare Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Baxter Healthcare Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Dietary Supplement","year":"2016","type":"Inapplicable","leadProduct":"Parenteral Nutrition","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"1","companyTruncated":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Ped3CB","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baxter Healthcare Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Baxter Healthcare Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Recombinant Antihemophilic Factor","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"11","companyTruncated":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Sodium Glycerophosphate","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Baxter Healthcare Corporation \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Baxter Healthcare Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Sulfite-Free Amino Acid","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Baxter Healthcare Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Baxter Healthcare Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"AUSTRALIA","productType":"Dietary Supplement","year":"2017","type":"Inapplicable","leadProduct":"Supplemental Parenteral Nutrition","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"JAPAN","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Tachosil","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase III","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Tisseel","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase III","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Baxter Healthcare Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Baxter Healthcare Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2013","type":"Inapplicable","leadProduct":"VCIV Modified Trivalent Influenza Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baxter Healthcare Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Baxter Healthcare Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"INDIA","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase IV","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"11","companyTruncated":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"ISRAEL","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"1","companyTruncated":"Baxter Healthcare Corporation \/ Baxter Healthcare Corporation"}]
Find Clinical Drug Pipeline Developments & Deals by Baxter Healthcare Corporation
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
